RT @AurelieRheumo: JUVE-BASIS Baricitinib in JIA Phase 3 RCT wk12 Cs or BioDMARDs IR â¡ï¸Time to disease flare HR 0.
Tweet Content
JUVE-BASIS Baricitinib in JIA
Phase 3 RCT wk12
Cs or BioDMARDs IR
⚡️Time to disease flare HR 0.24
⚡️JIA-ACR50% 63%
⚡️% flares 17% vs. 50% in PBO
Safety profile similar than adults
@RheumNow
#EULAR2022 LB0002 https://t.co/dX3DpB4QHT
Show on Archive Page
On
Display in Search Results
On
PDQ
Off